LLY-283 是一种有效的，选择性的，可口服的蛋白精氨酸甲基转移酶 5 (PRMT5) 抑制剂，对 PRMT5:MEP50 复合物的作用很强，IC50 和 Kd 值分别为 22 nM 和 6 nM，具有抗肿瘤活性。

LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.

LLY-283 is a potent, oral and selective arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM in vitro and 25 nM in cells, as well as a Kd of 6 nM for PRMT5:MEP50 complex in vitro; LLY-283 inhibits the proliferation of A375 cell with an IC50 of 46 nM[1].

LLY-283 (20 mg/kg; p.o., QD (once a day)) causes a significant inhibition on tumor growth in mice bearing A375 cells after treatment for 28 days[1].

2040291-27-6

C17H18N4O4

342.35

H2O:3.57 mg/mL (10.43 mM),ultrasonic and warming and heat to 60°C
DMSO:112.5mg/mL (328.6mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years